302 related articles for article (PubMed ID: 10787431)
1. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Batal R; Tremblay M; Barrett PH; Jacques H; Fredenrich A; Mamer O; Davignon J; Cohn JS
J Lipid Res; 2000 May; 41(5):706-18. PubMed ID: 10787431
[TBL] [Abstract][Full Text] [Related]
2. Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects.
Cohn JS; Tremblay M; Batal R; Jacques H; Veilleux L; Rodriguez C; Bernier L; Mamer O; Davignon J
J Lipid Res; 2002 Oct; 43(10):1680-7. PubMed ID: 12364552
[TBL] [Abstract][Full Text] [Related]
3. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.
Campos H; Perlov D; Khoo C; Sacks FM
J Lipid Res; 2001 Aug; 42(8):1239-49. PubMed ID: 11483625
[TBL] [Abstract][Full Text] [Related]
4. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions.
Fredenrich A; Giroux LM; Tremblay M; Krimbou L; Davignon J; Cohn JS
J Lipid Res; 1997 Jul; 38(7):1421-32. PubMed ID: 9254067
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size.
Breyer ED; Le NA; Li X; Martinson D; Brown WV
J Lipid Res; 1999 Oct; 40(10):1875-82. PubMed ID: 10508207
[TBL] [Abstract][Full Text] [Related]
7. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients.
Marcoux C; Tremblay M; Nakajima K; Davignon J; Cohn JS
J Lipid Res; 1999 Apr; 40(4):636-47. PubMed ID: 10191287
[TBL] [Abstract][Full Text] [Related]
8. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects.
Dinkel RE; Barrett PH; Demant T; Parhofer KG
Nutr Metab Cardiovasc Dis; 2006 Apr; 16(3):215-21. PubMed ID: 16580589
[TBL] [Abstract][Full Text] [Related]
9. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
Chan DC; Watts GF; Nguyen MN; Barrett PH
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
[TBL] [Abstract][Full Text] [Related]
10. Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.
Cohn JS; Batal R; Tremblay M; Jacques H; Veilleux L; Rodriguez C; Mamer O; Davignon J
J Lipid Res; 2003 Oct; 44(10):1976-83. PubMed ID: 12867543
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
Zheng C; Khoo C; Furtado J; Sacks FM
Circulation; 2010 Apr; 121(15):1722-34. PubMed ID: 20368524
[TBL] [Abstract][Full Text] [Related]
12. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
Ooi TC; Cousins M; Ooi DS; Steiner G; Uffelman KD; Nakajima K; Simo IE
J Clin Endocrinol Metab; 2001 Jul; 86(7):3134-42. PubMed ID: 11443178
[TBL] [Abstract][Full Text] [Related]
13. Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease.
Karpe F; Hellénius ML; Hamsten A
Metabolism; 1999 Mar; 48(3):301-7. PubMed ID: 10094104
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
[TBL] [Abstract][Full Text] [Related]
15. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia.
Cohn JS; Tremblay M; Batal R; Jacques H; Rodriguez C; Steiner G; Mamer O; Davignon J
Atherosclerosis; 2004 Nov; 177(1):137-45. PubMed ID: 15488876
[TBL] [Abstract][Full Text] [Related]
16. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
17. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
Chan DC; Nguyen MN; Watts GF; Barrett PH
J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
[TBL] [Abstract][Full Text] [Related]
18. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins.
Le NA; Gibson JC; Ginsberg HN
J Lipid Res; 1988 May; 29(5):669-77. PubMed ID: 3411241
[TBL] [Abstract][Full Text] [Related]
19. Identification and metabolic characteristics of an apolipoprotein C-II variant isolated from a hypertriglyceridemic subject.
Huff MW; Evans AJ; Wolfe BM; Connelly PW; Maguire GF; Strong WL
J Lipid Res; 1990 Mar; 31(3):385-96. PubMed ID: 2341805
[TBL] [Abstract][Full Text] [Related]
20. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.
Ooi EM; Chan DT; Watts GF; Chan DC; Ng TW; Dogra GK; Irish AB; Barrett PH
J Lipid Res; 2011 Apr; 52(4):794-800. PubMed ID: 21297177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
